⌘K

16:29:29·72d

SECFilingvia Quantisnow

Amendment: SEC Form SCHEDULE 13G/A filed by Fulcrum Therapeutics Inc.

ByQuantisnow·Wall Street's wire, on your screen.

FULC· Fulcrum Therapeutics Inc.

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

FULC
Fulcrum Therapeutics Inc.
Health Care

Recent analyst ratings

Jan 12UpdateAnalyst$20.00
Nov 24UpdateTruist-
Jul 29UpdateH.C. Wainwright$12.00
May 23UpdateLeerink Partners$12.00
May 15UpdateCantor Fitzgerald$10.00
Sep 13UpdateH.C. Wainwright$4.00

Related

SEC19h
SEC Form DEFA14A filed by Fulcrum Therapeutics Inc.
SEC19h
SEC Form DEF 14A filed by Fulcrum Therapeutics Inc.
SEC4d
SEC Form 10-Q filed by Fulcrum Therapeutics Inc.
SEC4d
Fulcrum Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
PR4d
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
PR4d
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
PR11d
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
SEC35d
Amendment: SEC Form SCHEDULE 13G/A filed by Fulcrum Therapeutics Inc.